Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 4Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Pathologic Complete Response 1Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Hemangiosarcoma 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Doxorubicin 69Radiotherapy 50Ifosfamide 48Gemcitabine 43Cyclophosphamide 36pazopanib 29Filgrastim 28pembrolizumab 26Docetaxel 26Nivolumab 23Surgical Procedures, Operative 21Etoposide 21Cisplatin 21Trabectedin 19Blood Specimen Collection 19Carboplatin 15Radiation 14Magnetic Resonance Spectroscopy 14Vincristine 13Bevacizumab 13anlotinib 12Temozolomide 12Peripheral Blood Stem Cell Transplantation 12Ipilimumab 12liposomal doxorubicin 11apatinib 11Radiosurgery 11Neoadjuvant Therapy 11Melphalan 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sarcoma × zanidatamab × Clear all
NCT07192068 2025-12-19

AcSé HER2

UNICANCER

Phase 2 Recruiting
105 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡